Articles

Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues

Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.

Read More

IU med school gets $9M for Alzheimer’s center

The grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.

Read More

Q&A

As an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur drugmakers to further innovation.

Read More

Ortho firms pull back on doc payments

The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.

Read More

Kaiser: Lack of competition endemic

In a new study, Indiana ranked as the 19th least-competitive state for individual health insurance and the 27th least-competitive for small-employer health insurance.

Read More

Zyprexa era comes to an end for Lilly

On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.

Read More

CNO Financial’s quarterly earnings, revenue rise

Carmel-based life and health insurer CNO Financial Group Inc. said Tuesday that its third-quarter earnings jumped nearly four times over last year's third-quarter results, but mostly because of a one-time tax-related gain.

Read More

FDA approves first generic versions of Zyprexa

Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.

Read More